<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825849</url>
  </required_header>
  <id_info>
    <org_study_id>16-19764</org_study_id>
    <nct_id>NCT02825849</nct_id>
  </id_info>
  <brief_title>Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair</brief_title>
  <acronym>PRP-E</acronym>
  <official_title>Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair: a Prospective Randomised Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with intrauterine adhesions (Asherman's Syndrome) and persistent thin endometrial
      lining in in vitro fertilization (IVF) treatment programs, particularly those resistant to
      standard therapies, present a significant clinical challenge. The aim of this trial is to
      assess if intrauterine administration of platelet rich plasma (PRP) improves endometrial
      lining thickness in patients with thin lining or Asherman's Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      There is a need for new and more effective therapies for patients with intrauterine adhesions
      (Asherman's Syndrome) and persistent thin endometrial lining in in vitro fertilization (IVF)
      treatment programs, particularly for patients resistant to standard therapies

      HYPOTHESIS:

      Platelet rich plasma stimulates cellular processes involved in endometrial regeneration
      relevant to management of a thin lining or intrauterine scarring.

      PRIMARY AIMS:

      - To measure the change in endometrial lining thickness

      SECONDARY AIMS:

        -  To determine if fertility is improved in patients receiving platelet rich plasma (PRP):

           1. In patients with thin lining undergoing frozen embryo transfer (FET), to determine:

        -  the chance of having embryo transfer,

        -  implantation rate

        -  clinical pregnancy rate

           2. In patients with Asherman's Syndrome, to determine:

        -  the rate of return/normalization of menses

        -  the chance of spontaneous pregnancy

        -  the chance of embryo transfer

      Any adverse effects of study arm will be monitored and reported as appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>3-30 days after treatment</time_frame>
    <description>Endometrial thickness will be measured using transvaginal ultrasound per standard protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate (for patients with thin lining)</measure>
    <time_frame>approximately 7 weeks after treatment</time_frame>
    <description>defined by number of gestational sacs seen on early pregnancy 6-week ultrasound divided by number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate (for patients with thin lining)</measure>
    <time_frame>approximately 7 weeks after treatment</time_frame>
    <description>Defined by the number of fetal poles with heartbeat seen on 6-week ultrasound divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return/normalization of menstrual flow (for patients with Asherman's Syndrome)</measure>
    <time_frame>1-3 months after treatment</time_frame>
    <description>Patients will be asked to record the menstrual flow diary (Menstrual Assessment Chart) before treatment and for 1-3 months after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infertility</condition>
  <condition>Asherman's Syndrome</condition>
  <arm_group>
    <arm_group_label>PRP intrauterine infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group with standard treatment only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intrauterine infusion of platelet rich plasma</intervention_name>
    <description>Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.</description>
    <arm_group_label>PRP intrauterine infusion</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent thin lining &lt; 6mm on &gt;1 cycle in previous IVF or FET cycle OR
             moderate-to-severe Asherman's syndrome

        Exclusion Criteria:

          -  Age &lt;18 years old or &gt;43 years old,

          -  Pregnancy,

          -  Diagnosis of cancer,

          -  Hb &lt;11 g/dL, platelets &lt;150,000/mm3,

          -  Anticoagulation,

          -  NSAIDs in the 10 days before procedure

          -  Any significant comorbidity or psychiatric disorder that would compromise patient
             safety or compliance, interfere with consent, study participation, follow up, or
             interpretation of study results.

          -  Incision in the uterus: myomectomy; cesarean section
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather G. Huddleston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lusine Aghajanova, MD, PhD</last_name>
    <phone>415-353-7475</phone>
    <email>lusine.aghajanova@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather G. Huddleston, MD</last_name>
    <phone>415-353-7475</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco - Center for Reproductive Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lusine Aghajanova, MD, PhD</last_name>
      <phone>415-353-7475</phone>
      <email>lusine.aghajanova@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather G. Huddleston, MD</last_name>
      <phone>415-353-7475</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrium</keyword>
  <keyword>thin uterine lining</keyword>
  <keyword>uterine scarring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

